fluanisone profile

Fluanisone is a butyrophenone derivative with antipsychotic activity. It is a non-selective dopamine receptor antagonist with high affinity for D2 receptors. Fluanisone is used to treat schizophrenia and other psychotic disorders. It is also used to manage agitation and anxiety in patients with dementia. The synthesis of fluanisone involves a multi-step process starting from 4-fluoro-benzophenone. The compound exhibits a wide range of effects including antipsychotic, anxiolytic, and sedative effects. Fluanisone is studied due to its unique pharmacological profile and potential therapeutic applications in treating various neuropsychiatric disorders. It is also used as a research tool to investigate the role of dopamine in the brain.'

fluanisone: former provisional as haloanisone; structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	15139
CHEMBL ID	58792
CHEBI ID	177744
SCHEMBL ID	145054
MeSH ID	M0046290

Synonym
1-(4-luorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one
CHEBI:177744
haloanison
fluanisone
1-butanone, 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)-1-piperazinyl]-
nsc170977
2028 md
metorin
sedalande
4'-fluoro-4-[4-(o-methoxyphenyl)-1-piperazinyl]butyrophenone
4-[4-(o-methoxyphenyl)-1-piperazinyl]-p-fluorobutyrophenone
haloanisone
butyrophenone, 4'-fluoro-4-[4-(o-methoxyphenyl)-1-piperazinyl]-
r 2028
anti-pica
fluanison
1480-19-9
md 2028
wln: t6n dntj a3vr df& dr bo1
r 2167
nsc-170977
4'-fluoro-4-(4-(o-methoxyphenyl)-1-piperazinyl)butyrophenone
brn 0707524
1-butanone, 1-(4-fluorophenyl)-4-(4-(2-methoxyphenyl)-1-piperazinyl)-
fluanisona [inn-spanish]
fluanisone [inn:ban:dcf]
butyrophenone, 4'-fluoro-4-(4-(o-methoxyphenyl)-1-piperazinyl)-
fluanisonum [inn-latin]
4-(4-(o-methoxyphenyl)-1-piperazinyl)-p-fluorobutyrophenone
nsc 170977
einecs 216-038-8
D02621
fluanisone (inn)
OPREA1_227293
OPREA1_528183
smr000111851
MLS000107485
AKOS003669652
r-2028
CHEMBL58792 ,
md-2028
r-2167
1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one
L000740
FT-0668561
1-(4-fluoro-phenyl)-4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butan-1-one
bdbm50019959
1-(4-fluoro-phenyl)-4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butan-1-one(fluanisone)
A808723
NCGC00077304-02
1d0w98u1i4 ,
fluanisona
fluanisonum
unii-1d0w98u1i4
5-23-02-00213 (beilstein handbook reference)
tox21_110992
dtxcid2025711
cas-1480-19-9
dtxsid4045711 ,
NCGC00077304-01
HMS2231H24
4'-fluoro-4-)4-(o-methoxyphenyl)-1-piperazinyl)butyrophenone
fluanisone [who-dd]
fluanisone [mart.]
fluanisone [mi]
fluanisone [inn]
HMS3373P06
SCHEMBL145054
REGID_FOR_CID_15139
hypnorm (salt/mix)
1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)-1-piperazinyl]-1-butanone #
solusediv (salt/mix)
p-fluoro-.gamma.-[4-(o-methoxyphenyl)-1-piperazinyl]butyrophenone
sedavic (salt/mix)
IRYFCWPNDIUQOW-UHFFFAOYSA-N
4'-fluoro-4-[4(o-methoxyphenyl)-1-piperazinyl]buterophenone
SR-01000215056-1
sr-01000215056
Q5462605
DB13665
1-(4-fluorophenyl)-4-(4-(2-methoxyphenyl)piperazin-1-yl)butan-1-one
2028 md; nsc 170977; r 2028
BCP12114
SY267068
mfcd00366636
1-butanone,1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)-1-piperazinyl]-

Excerpt	Reference	Relevance
"When establishing a rabbit model for cardiovascular research in our laboratory we have used midazolam in combination with fentanyl/fluanisone (MFF) and nitrous oxide as anaesthesia."	( Midazolam in combination with fentanyl/fluanisone and nitrous oxide as anaesthesia in rabbits--cardiovascular parameters. Fosse, RT; Hessevik, I; Hexeberg, E; Hexeberg, S, 1995)	0.76

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
aromatic ketone	A ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	19.6707	0.0008	11.3822	44.6684	AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	6.3096	0.0123	7.9835	43.2770	AID1346984
pregnane X nuclear receptor	Homo sapiens (human)	Potency	7.9433	0.0054	28.0263	1,258.9301	AID1346985
P53	Homo sapiens (human)	Potency	35.4813	0.0731	9.6858	31.6228	AID504706
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	13.0682	0.0007	23.0674	1,258.9301	AID743085; AID743122
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	79.4328	3.5481	19.5427	44.6684	AID743266
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	1.4125	0.0178	9.6374	44.6684	AID588834
DNA polymerase beta	Homo sapiens (human)	Potency	89.1251	0.0224	21.0102	89.1251	AID485314
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	36.1254	0.0056	12.3677	36.1254	AID624032
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	31.6228	0.3162	12.7657	31.6228	AID881
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	31.6228	0.0063	8.2350	39.8107	AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 2C	Rattus norvegicus (Norway rat)	Ki	0.0520	0.0002	0.6677	10.0000	AID5218; AID5294
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	Ki	0.0520	0.0001	0.6017	10.0000	AID5218; AID5294
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0009	0.0001	0.9490	10.0000	AID35421; AID37170
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	0.0010	0.0001	0.7396	10.0000	AID4425
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0009	0.0000	0.5751	10.0000	AID35421; AID37170
5-hydroxytryptamine receptor 2B	Rattus norvegicus (Norway rat)	Ki	0.0520	0.0002	0.5909	10.0000	AID5218; AID5294
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0009	0.0000	0.9650	10.0000	AID35421; AID37170
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.0027	0.0000	0.4375	10.0000	AID63823; AID65108; AID65884
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (96)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID133847	Anticonvulsant activity against electroshock-induced convulsions, after 5 hour of peroral administration in mouse at a dose of 40 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID133855	Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 40 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID135364	Inhibitory activity against tremorine-induced tremors, after 1 hour of peroral administration in mouse at a dose of 60 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID139321	Inhibitory activity against pentobarbital induced-sleeping after 5 hr of peroral administration in mouse; NT means not tested	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID23961	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID128987	Anticonvulsant activity against tryptamine-induced convulsions, after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID23968	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID128671	Antagonism of apomorphine-induced climbing behavior in mice after peroral administration	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID131206	Contractile activity in skeletal muscles, after 5 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID183181	Antagonistic activity against apomorphine-induced stereotypy, after 5 hour of peroral administration in rats at a dose of 100 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID63305	Inhibitory activity against apomorphine induced emesis, after 1 hr of peroral administration in dog; NT means not tested	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID23959	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID113114	Antagonism of apomorphine-induced climbing in mice when administered intraperitoneally 60 min prior to apomorphine (1 mg/kg)	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID131589	Suppression of aggressive behavior, after 5 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177741	Activity to evoke catalepsy, after 1 hour of peroral administration in rats	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID4029	Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.	1997	Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3	5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.
AID63328	Antagonistic activity against apomorphine-induced emesis, after 5 hour of peroral administration in dogs	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID26296	Partition coefficient (logD7.4)	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID5294	Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID134580	Lethal dose in mice (LD50) following i.p. dosing	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177948	Antagonistic activity against amphetamine-induced stereotypy, after 1 hour of peroral administration in rats	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID23970	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID197391	Inhibitory activity against body weight gain after 5 hr of peroral administration in rat; NT means not tested	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID135368	Inhibitory activity against tremorine-induced tremors, after 5 hour of peroral administration in mouse at a dose of 60 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID128819	Antagonistic activity against amphetamine-induced hypermotility, after 5 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID37170	Ability to inhibit [3H]WB-4101 binding to alpha-1 adrenergic receptor was determined in rat	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID65884	Displacement of [3H]-Spiperone from Dopamine receptor D2 in rat striatum	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID5218	Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID176808	Suppression of conditioned avoidance behavior in rats when administered perorally 60 min before measurement	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID139322	Inhibitory activity against tryptamine induced convulsions after 5 hr of peroral administration in mouse; NT means not tested	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID139319	Inhibitory activity against apomorphine induced turning, after 5 hr of peroral administration in mouse; NT means not tested	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177952	Antagonistic activity against apomorphine-induced stereotypy in rats, by administering perorally	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID130908	Inhibition of spontaneous motor activity after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID133681	Activity of inclined screen in mouse, after 5 hour of peroral administration in mouse at a dose of 60 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID178998	Inhibitory activity against norepinephrine-induced lethality, after 5 hour of peroral administration in rat	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID130909	Inhibition of spontaneous motor activity after 5 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID178997	Inhibitory activity against norepinephrine-induced lethality, after 1 hour of peroral administration in rat	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177724	Induction of catalepsy in rats when administered intraperitoneally 4 hr prior to measurement to groups of nine animals	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID23973	Partition coefficient (logD, measured by HPLC, log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID231638	Binding affinity against the D2 dopamine receptor and ratio of IC50(+Na+) / IC50(-Na(+)) [from 2-4 experiments]	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID19647	Partition coefficient (logP)	1997	Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3	5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.
AID177725	Induction of catalepsy in rats when administered intraperitoneally 4 hr prior to measurement to groups of 9 animals. value is based on at least three dose levels(40% of animals showed catalepsy)	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID226319	Activity calculated as Na+ ratio [IC50 (+Na+) / IC50 (-Na+)]	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID130874	Inhibition against apomorphine-induced climbing, after 5 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID131419	Potentiation against pentobarbital-induced sleeping, after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID131588	Suppression of aggressive behavior, after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID131204	Contractile activity in skeletal muscles, after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID128818	Antagonistic activity against amphetamine-induced hypermotility, after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID133845	Anticonvulsant activity against electroshock-induced convulsions, after 1 hour of peroral administration in mouse at a dose of 40 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID176663	Suppression of conditioned avoidance behavior in rats following p.o. administration.	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID63823	pKi value against rat Dopamine receptor D2.	1997	Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3	5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.
AID176326	Body weight gain, after 2 hour of period of conditioned feeding in rats,	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID135224	Inhibitory activity against tremorine-induced salivation, after 5 hour of peroral administration in mouse at a dose of 60 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID128670	Antagonism of apomorphine-induced climbing behavior in mice after ip administration	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID128815	Antagonistic activity against amphetamine-induced Hypermobility in mouse by administering perorally	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID35421	Potency to displace [3H]- WB-4101 from alpha-1 adrenergic receptor in rat striatum	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID177954	Antagonistic activity against apomorphine-induced stereotypy, after 1 hour of peroral administration in rats	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID133859	Anticonvulsant activity against pentylenetetrazole-induced convulsions, after 5 hour of peroral administration in mouse at a dose of 40 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID135222	Inhibitory activity against tremorine-induced salivation, after 1 hour of peroral administration in mouse at a dose of 60 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177742	Activity to evoke catalepsy, after 5 hour of peroral administration in rats	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID4425	pKi value against rat 5-hydroxytryptamine 1A receptor.	1997	Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3	5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.
AID113115	Antagonism of apomorphine-induced climbing in mice when administered perorally 60 min prior to apomorphine (1 mg/kg)	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID176807	Suppression of conditioned avoidance behavior in rats when administered intraperitoneally 60 min before measurement	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID130911	Inhibition of spontaneous motor activity in mouse, by administering perorally	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID134519	Effect on skeletal muscle tone, after 1 hour of peroral administration in mouse at a dose of 100 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177732	Inhibition against conditioned avoidance response, after 5 hour of peroral administration in rats	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID130873	Inhibition against apomorphine-induced climbing, after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177949	Antagonistic activity against amphetamine-induced stereotypy, after 5 hour of peroral administration in rats	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID23965	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID128162	Activity of inclined screen in mouse, after 1 hour of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID176662	Suppression of conditioned avoidance behavior in rats after ip administration	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2.
AID65108	In vitro displacement of [3H]spiperone from Dopamine receptor D2 binding site in rat striatum.	1997	Journal of medicinal chemistry, Jan-31, Volume: 40, Issue:3	5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.
AID23971	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID64931	Ability to inhibit the [3H]spiperone binding to striatum Dopamine receptor D2 was determined in rat	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
AID23963	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID177739	Activity to evoke catalepsy in rats, by administering perorally	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID177731	Inhibition against conditioned avoidance response, after 1 hour of peroral administration in rats	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID130877	Inhibition against apomorphine-induced turning, after 1 hr of peroral administration in mouse	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID134522	Effect on skeletal muscle tone, after 5 hour of peroral administration in mouse at a dose of 100 mg/kg	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	25 (45.45)	18.7374
1990's	11 (20.00)	18.2507
2000's	7 (12.73)	29.6817
2010's	9 (16.36)	24.3611
2020's	3 (5.45)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (5.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (1.67%)	4.05%
Observational	0 (0.00%)	0.25%
Other	56 (93.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	1.96	1	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
benzene [no description available]	1.96	1	0	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
creatine [no description available]	1.94	1	0	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
nitrous oxide Nitrous Oxide: Nitrogen oxide (N2O). A colorless, odorless gas that is used as an anesthetic and analgesic. High concentrations cause a narcotic effect and may replace oxygen, causing death by asphyxia. It is also used as a food aerosol in the preparation of whipping cream.. dinitrogen oxide : A nitrogen oxide consisting of linear unsymmetrical molecules with formula N2O. While it is the most used gaseous anaesthetic in the world, its major commercial use, due to its solubility under pressure in vegetable fats combined with its non-toxicity in low concentrations, is as an aerosol spray propellant and aerating agent for canisters of 'whipped' cream.	6.98	1	0	gas molecular entity; nitrogen oxide	analgesic; bacterial metabolite; food packaging gas; food propellant; general anaesthetic; greenhouse gas; inhalation anaesthetic; NMDA receptor antagonist; raising agent; refrigerant; vasodilator agent
1-(2-methoxyphenyl)piperazine 1-(2-methoxyphenyl)piperazine: RN given refers to parent cpd	1.99	1	0	piperazines
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	1.96	1	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	1.97	1	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	2.01	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
chloral hydrate [no description available]	2	1	0	aldehyde hydrate; ethanediol; organochlorine compound	general anaesthetic; mouse metabolite; sedative; xenobiotic
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	1.96	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.37	2	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	1.96	1	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.	1.96	1	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	1.96	1	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	8.22	6	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
dibucaine Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions.	1.96	1	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
benzophenone benzophenone : The simplest member of the class of benzophenones, being formaldehyde in which both hydrogens are replaced by phenyl groups.	1.96	1	0	benzophenones	photosensitizing agent; plant metabolite
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	1.96	1	0	dibenzooxepine; tertiary amino compound	antidepressant
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	6.58	27	2	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	3.2	6	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	1.96	1	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	1.96	1	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	2.72	3	0	organofluorine compound	inhalation anaesthetic
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.69	3	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	1.94	1	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	1.96	1	0	piperidinecarboxamide	drug allergen; local anaesthetic
mesoridazine Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.	1.96	1	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	6.21	18	2	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
moperone moperone: RN given refers to parent cpd; structure	6.96	1	0	aromatic ketone
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	1.96	1	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	8.24	6	0	barbiturates	GABAA receptor agonist
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	1.96	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
pipamperone pipamperone: RN given refers to parent cpd; structure. pipamperone : A member of the class of bipiperidines that is 1,4'-bipiperidine which is substituted at the 1' and 4' positions by 4-(p-fluorophenyl)-4-oxobutyl and carboxamide groups, respectively. A first generation antipsychotic, its properties are generally similar to those of haloperidol.	6.96	1	0	aromatic ketone; bipiperidines; monocarboxylic acid amide; organofluorine compound; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	1.96	1	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	1.96	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	1.96	1	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	8.8	2	1	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	3.34	1	1	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	1.96	1	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
trifluoperazine [no description available]	1.96	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trifluperidol Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)	2.34	2	0	aromatic ketone
urethane [no description available]	9.3	4	1	carbamate ester	fungal metabolite; mutagen
xylazine Xylazine: An adrenergic alpha-2 agonist used as a sedative, analgesic and centrally acting muscle relaxant in VETERINARY MEDICINE.. xylazine : A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.	2	1	0	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
corticosterone [no description available]	1.97	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	1.99	1	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
tribromoethanol tribromoethanol: major descriptor (66-90); on-line search ETHANOL (66-90); INDEX MEDICUS search TRIBROMOETHANOL (66-90)	8.39	1	1	alcohol; organobromine compound
phenylpiperazine phenylpiperazine: RN given refers to parent cpd	1.99	1	0
nitrobenzene nitrobenzene : A nitroarene consisting of benzene carrying a single nitro substituent. An industrial chemical used widely in the production of aniline.	1.96	1	0	nitroarene; nitrobenzenes
anisole anisole : A monomethoxybenzene that is benzene substituted by a methoxy group.	1.96	1	0	monomethoxybenzene	plant metabolite
chlorobenzene [no description available]	1.96	1	0	monochlorobenzenes	solvent
methohexital Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.	2.01	1	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	1.96	1	0	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	1.96	1	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
acetophenazine acetophenazine: major descriptor (73-85); minor descriptor (64-72); on-line search PHENOTHIAZINES (64-85); Index Medicus search PHENOTHIAZINES (64-72); ACETOPHENAZINE (73-85); RN given refers to parent cpd. acetophenazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.	1.96	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; phenothiazines	phenothiazine antipsychotic drug
etorphine Etorphine: A narcotic analgesic morphinan used as a sedative in veterinary practice.	1.96	1	0
hypnorm Hypnorm: contains fentanyl & fluanisone	6.98	1	0
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	1.96	1	0	tryptamines
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	7.17	1	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flesinoxan [no description available]	1.99	1	0
eltoprazine eltoprazine: RN given refers to parent cpd; suppresses hyperpolarizing responses to serotonin in rat hippocampus	1.99	1	0
medetomidine Medetomidine: An agonist of RECEPTORS, ADRENERGIC ALPHA-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of DEXMEDETOMIDINE.	2.93	4	0	imidazoles
lr 511 LR 511: structure	1.97	1	0
atipamezole [no description available]	1.98	1	0
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	1.96	1	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
dextromoramide Dextromoramide: An opioid analgesic structurally related to METHADONE and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070). dextromoramide : An N-acylpyrrolidine arising by formal condensation of pyrrolidine with (3S)-3-methyl-4-(morpholin-4-yl)-2,2-diphenylbutanoic acid. An opioid analgesic that is structurally related to methadone, it is more poweful than morphine but shorter acting. It has been used (particularly as the hydrogen tartrate salt) for the treatment of severe pain, but was discontinued in the UK in 2004.	1.94	1	0	morpholines; N-acylpyrrolidine	opioid analgesic
alphaxalone alphaxalone: RN given refers to (3alpha,5alpha)-isomer; structure	1.98	1	0	corticosteroid hormone
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.01	1	0
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	1.96	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
buprenorphine Buprenorphine: A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.. buprenorphine : A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain.	2.41	2	0	morphinane alkaloid	delta-opioid receptor antagonist; kappa-opioid receptor antagonist; mu-opioid receptor agonist; opioid analgesic
chlorprothixene Chlorprothixene: A thioxanthine with effects similar to the phenothiazine antipsychotics.. (Z)-chlorprothixene : A chlorprothixene in which the double bond adopts a (Z)-configuration.	1.96	1	0	chlorprothixene
thiobarbital thiobarbital: structure	1.98	1	0
levosulpiride (S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).	1.97	1	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	1.98	1	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
17-ketosteroids 17-Ketosteroids: Steroids that contain a ketone group at position 17.. 17-oxo steroid : Any oxo steroid carrying the oxo group at position 17.	1.94	1	0
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	1.98	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
morphinans Morphinans: Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.	1.96	1	0	isoquinoline alkaloid fundamental parent; morphinane alkaloid
chloralose Chloralose: A derivative of CHLORAL HYDRATE that was used as a sedative but has been replaced by safer and more effective drugs. Its most common use is as a general anesthetic in animal experiments.	8.39	1	1
alphadolone alphadolone: RN given refers to (3alpha,5alpha)-isomer	2.38	2	0
gastrins Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.	2	1	0
piperidines Piperidines: A family of hexahydropyridines.	1.96	1	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.01	1	0
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.37	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic

Condition	Indicated	Relationship Strength	Studies	Trials
Anochlesia [description not available]	0	1.97	1	0
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0
Arrhythmia [description not available]	0	7.17	1	0
Cardiovascular Stroke [description not available]	0	2.17	1	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	0	2.17	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	7.17	1	0
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	0	5.57	9	2
Behavior Disorders [description not available]	0	4.42	5	1
Psychoses [description not available]	0	2.63	3	0
Symptom Cluster [description not available]	0	1.93	1	0
Cerebral Arteriosclerosis [description not available]	0	1.93	1	0
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	0	4.42	5	1
Intracranial Arteriosclerosis Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.	0	1.93	1	0
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	1	4.63	3	0
Syndrome A characteristic symptom complex.	0	1.93	1	0
Deficiency, Mental [description not available]	0	2.34	2	0
Absence Seizure [description not available]	0	1.93	1	0
Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)	0	2.34	2	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	0	1.93	1	0
Dementia Praecox [description not available]	0	4.24	4	1
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	0	4.24	4	1
Affective Psychosis, Bipolar [description not available]	0	1.94	1	0
Paranoia [description not available]	0	2.34	2	0
Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.	0	1.94	1	0
Catatonia A neuropsychiatric disorder characterized by one or more of the following essential features: immobility, mutism, negativism (active or passive refusal to follow commands), mannerisms, stereotypies, posturing, grimacing, excitement, echolalia, echopraxia, muscular rigidity, and stupor; sometimes punctuated by sudden violent outbursts, panic, or hallucinations. This condition may be associated with psychiatric illnesses (e.g., SCHIZOPHRENIA; MOOD DISORDERS) or organic disorders (NEUROLEPTIC MALIGNANT SYNDROME; ENCEPHALITIS, etc.). (From DSM-IV, 4th ed, 1994; APA, Thesaurus of Psychological Index Terms, 1994)	0	1.94	1	0
Brain Damage, Chronic A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.	0	2.34	2	0
Brain Disorders [description not available]	0	1.94	1	0
Aura [description not available]	0	1.94	1	0
Agitation, Psychomotor [description not available]	0	2.34	2	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	0	1.94	1	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	0	1.94	1	0
Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.	0	2.34	2	0
Acute Brain Injuries [description not available]	0	1.94	1	0
Child Behavior Disorders Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns.	0	1.94	1	0
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	0	1.94	1	0
Metabolic Acidosis [description not available]	0	2.36	2	0
Hypercapnia A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.	0	1.96	1	0
Acidosis A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.	0	2.36	2	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.37	2	0
Absence Seizure Disorder [description not available]	0	1.98	1	0
Epilepsy, Absence A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736)	0	1.98	1	0
Glial Cell Tumors [description not available]	0	1.99	1	0
Benign Neoplasms [description not available]	0	1.99	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	1.99	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	1.99	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	1.99	1	0
Cirrhosis, Liver [description not available]	0	1.99	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	0	1.99	1	0
Consciousness, Loss of [description not available]	0	2	1	0
Weight Reduction [description not available]	0	2	1	0
Weight Loss Decrease in existing BODY WEIGHT.	0	2	1	0
Gastric Fistula Abnormal passage communicating with the STOMACH.	0	2	1	0
Complication, Postoperative [description not available]	0	2.01	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	0	2.01	1	0
Femoral Fractures Fractures of the femur.	0	1.96	1	0

fluanisone

Description

Cross-References

Synonyms (86)

Research Excerpts

Compound-Compound Interactions

Bioavailability

Drug Classes (1)

Protein Targets (20)

Potency Measurements

Inhibition Measurements

Biological Processes (21)

Molecular Functions (8)

Ceullar Components (8)

Bioassays (96)

Research

Studies (55)

Market Indicators

Research Demand Index: 28.55

Study Types

fluanisone

Description

Cross-References

Synonyms (86)

Research Excerpts

Compound-Compound Interactions

Bioavailability

Drug Classes (1)

Protein Targets (20)

Potency Measurements

Inhibition Measurements

Biological Processes (21)

Molecular Functions (8)

Ceullar Components (8)

Bioassays (96)

Research

Studies (55)

Market Indicators

Research Demand Index: 28.55

Study Types

Related Drugs (82)

Related Conditions (56)